Biostage (OTCMKTS:BSTG) & Interpace Biosciences (OTCMKTS:IDXG) Financial Comparison

Biostage (OTCMKTS:BSTG) and Interpace Biosciences (OTCMKTS:IDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Biostage and Interpace Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostage	0	0	1	0	3.00
Interpace Biosciences	0	0	0	0	0.00

Earnings & Valuation

This table compares Biostage and Interpace Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67
Interpace Biosciences	$38.73 million	0.19	$24.58 million	($0.05)	-33.60

Interpace Biosciences has higher revenue and earnings than Biostage. Interpace Biosciences is trading at a lower price-to-earnings ratio than Biostage, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

5.7% of Interpace Biosciences shares are held by institutional investors. 15.3% of Biostage shares are held by insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Biostage and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostage	N/A	N/A	-174.43%
Interpace Biosciences	65.25%	219.07%	105.05%

Risk and Volatility

Biostage has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Summary

Interpace Biosciences beats Biostage on 8 of the 12 factors compared between the two stocks.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.